The Hague, 2 June 2021 –EHA congratulates nine talented researchers in hematology on their receipt of the EHA Research Grants 2021 after a rigorous selection process.

Live days: April 29-30, 2021 Content available: April 22, 2021 – May 29, 2021 Chair: Prof Dr C Dufour Junior and senior hematologists from all over the world gathered on April 29-30, 2021…

Urgent actions are needed now to prevent a collapse of diagnostic testing.

After more than a decade of tireless work to further EHA’s mission our Executive Director, Carin Smand, has unfortunately announced that she will be leaving our organization.

November 2020 – April 2021 In the past six months, hematologists, clinicians, transfusion medicine specialists, oncologists, special nurses and researchers gathered virtually for the first EHA Guidelines Workshop series.

In 2020, EHA launched the Taskforce on Diversity, Equity, and Inclusion with an EHA Board mandate.

Dear GoCART community,  With more than 1500 CAR-T infusions registered in the EBMT registry, EHA and EBMT are proud to announce a series of scientific calls within Work Package 6: Scientific…

VIRTUAL: EHA-PTHiT Hematology Mini Tutorial April 12 -13, 2021 Meeting Chairs: Prof G Gaidano (European Hematology Association) Prof I Hus (Polish Society of Hematology and Transfusion) Prof T Robak (Polish Society of Hematology and Transfusion) As…

October 26-31, 2020 | Virtual Global Conference Steering Committee: B Andemariam, A Campbell, M Cappellini, S Chakravorty,  R Colombatti, B Inusa, R Kesse-Adu, D Rees, A Taher, M Treadwell In the last…

October 26-31, 2020 | Virtual Global Conference Steering Committee: B Andemariam, A Campbell, M Cappellini, S Chakravorty,  R Colombatti, B Inusa, R Kesse-Adu, D Rees, A Taher, M Treadwell In the last…

Dates: February 4-6, 2021 Chairs: H Einsele (EHA) & C Chabannon (EBMT) For the 3rd time now the European Hematology Association (EHA) and the European Society for Blood and Marrow Transplantation (EBMT)…

"We (women) need to empower ourselves, learn to be confident and understand that are many ways of being a successful researcher and leader. But to make this possible we need institutions and research associations to help us by providing secure networks, structures and resources that help in boosting this change.” - Dr Alba Maiques-Diaz (Spain).

T2EVOLVE is a new breakthrough alliance of academic and industry leaders in cancer immunotherapy under the European Union's Innovative Medicines Initiative (IMI). The key objective of T2EVOLVE is to accelerate development and increase awareness and access of cancer patients to immunotherapy with immune cells that harbor a genetically engineered T cell receptor (TCR) or synthetic chimeric antigen receptor (CAR). Simultaneously, T2EVOLVE aims to provide guidance on sustainable integration of these treatment into the EU healthcare system.

This scientific meeting was organized together with the EHA Scientific Working Group on Immune Therapies for Hematological Disorders.

November 13, 2020 Meeting Chairs: Prof J Gribben (European Hematology Association) Prof G Stemmelin (Argentinian Society of Hematology) On November 13, EHA and the Argentinian Society of Hematology (SAH) kicked-off the second…